Dexcom Shares Plummet Despite Beating Q3 Expectations

The company's stock fell sharply following a slight decline in U.S. revenue and an executive transition announcement.

Dexcom reported Q3 earnings of 45 cents per share, surpassing analyst expectations of 43 cents.
The company's revenue for the quarter was $994.2 million, slightly above the projected $990 million.
Despite the earnings beat, Dexcom's U.S. revenue fell by 2%, contributing to a significant drop in its stock price.
The company maintained its full-year revenue guidance of $4 billion to $4.05 billion, unchanged from previous forecasts.
Dexcom announced the retirement of Chief Commercial Officer Teri Lawver, with CEO Kevin Sayer temporarily assuming her duties.